NEW YORK, February 25, 2013 /PRNewswire/ --
Today, National Traders Association announced new research reports highlighting Newmont Mining Corp (NYSE:NEM), AMETEK, Inc. (NYSE: AME), Honeywell International Inc. (NYSE: HON), Amgen, Inc. (NASDAQ:AMGN) and Bristol Myers Squibb Co. (NYSE:BMY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Newmont Mining Corp Research Report
Meanwhile, gold producer Newmont produced 1.3 million ounces of attributable gold, with sales of 1.2 million ounces for the fourth quarter of 2012. Attributable gold production for the year was at 5 million ounces with sales of 4.9 million ounces. It expects to produce 4.8 million to 5.1 million ounces of gold this year, while gold price-linked dividend will increase 21 percent year over year to 42.5 cents per share for Q1 this year. Newmont aims to advance its pipeline projects that are expected to be profitable, including its projects in Ghana and Indonesia. Metals Channel put Newmont in rank #22 in its Metals Channel Global Mining Titans Index, a list of the top 50 global leaders in the metals and mining sector. The Full Research Report on Newmont Mining Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/9aa3_NEM]
AMETEK, Inc. Research Report
Ametek reported record levels of orders, sales, operating income, operating margins, and net income for the fourth quarter, showing strength in all areas of the company. The company expects the business to show solid growth in 2013, especially in its oil and gas, power and aerospace segments. In the coming year, it will continue to invest in product development, geographic expansion, and strategic acquisitions.
Recently, Ametek acquired Sunpower, Inc., a leader in cryogenic cooling and heated Stirling engine technology and Crystal Engineering's high-end, portable calibration instruments. It also expanded its position in aerospace aftermarket by acquiring Aero Components International (ACI) and Avtech Avionics and Instruments. The Full Research Report on AMETEK, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/e0d7_AME]
Honeywell International Inc. Research Report
Honeywell's materials unit topped all other segments in terms of sales growth, up 8 percent, as it supplies chemicals and equipment used in oil and gas production. Since US oil production is increasing at a substantial rate, it is understandable how this segment did well in the recent quarter. The company was also granted patent protection for its avionics display system, a system that includes navigation, communications and display systems that will easily provide flight information to pilots and crew members. Embraer has signed a $2.8 billion contract with Honeywell for this technology and will use it to develop a second-generation E-Jet aircraft family and it. Honeywell CEO David Cote warns, however, that uncertain macroeconomic conditions could change the fate of technology manufacturers. He calls for policy leaders to address the nation's rising debt load by cutting government spending. While he admits that cuts in the country's defense budget could hurt his company, he also argues it will be more than overshadowed by the benefits that the country can get in the coming years by having another trillion dollars of debt reduction. The Full Research Report on Honeywell International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/86a4_HON]
Amgen, Inc. Research Report
Amgen, the biggest in its industry, has been responding to expired patents using aggressive dividend payments and stock buybacks to lift share prices. Its drugs that have declined or stagnant demand have been given price increases to stabilize revenue. The company has also been an active lobbyist, spending as much as $42 million in 2009, and was able to secure key legislative gains. Amgen still has a couple of drugs which could give optimism to the company's future, like arthritis drug Enbrel. The drug generated $4.23 billion in sales last year, and is one of a few drugs that contributed to the gains of the company's stock over the past 18 months. The patent won't be expired until 2028. Upcoming drugs that are showing promise are treatments for high cholesterol and osteoporosis in one or two years, while a drug for ovarian cancer is expected to release late-stage data this year. In addition, it has partnered with Actavis Inc. in a developmental deal which could bring Amgen to the biosimilar market. However, these weren't enough to please some analysts and they are doubtful that the company may be able to continue to satisfy investors in the long run. In addition, growing competition from rivals and increased regulatory scrutiny could add insult to injury as well. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/767e_AMGN]
Bristol Myers Squibb Co. Research Report
Bristol-Myers was recently hit by lapsed drug patents last year, as demand for its blood clot preventer Plavix - once one of the world's best-selling drugs - fell 97 percent after the patent expired in May, while its blood pressure drugs Avapro and Avalide fell 57 percent after their patents expired in March. The company, as well as its competitors, has also been losing market share from low-cost generic drugs, which also forced Bristol-Myers to cut costs and develop new products in the market to safeguard itself from expired patents. Bristol-Myers is currently looking for a buyer for their brand portfolio in Mexico and Brazil, which could fetch in $750 million. The deal would be the latest of its many previous consumer divestitures in recent years, including the spin-off of Mead Johnson Nutrition Co, a baby-food products manufacturer. It is also improving its efforts in its diabetes treatment drug by partnering with AstraZeneca, by merging their diabetes marketing teams for the development of the pill Onglyza and a combination pill combining the pill and the generic metformin. The Full Research Report on Bristol Myers Squibb Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers